Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Atara Biotherapeutics Inc (ATRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.96-4.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.94 → 0.94 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ATRA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating expenses decline significantly year-over-year | Atara is cutting costs sharply, aiming for a 60% drop in operating expenses in 2025. | Intact | operating expenses do not decline by at least 60% in FY25 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “• Research and development expenses were $1.3 million for the second quarter 2026, as compared to $7.3 million for the same period in 2025.” “• General and administrative expenses were $3.8 million for the second quarter 2026, as compared to $6.5 million for the same period in 2025.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotechnology business with high risk, not a proven compounder. Its long-term thesis is in a watch state: management is reducing expenses and preparing a renewed regulatory submission, but recent financial performance remains weak.
The valuation model indicates ATRA trades at a premium to peers, while confidence in that assessment is low. The expectations gap is modest, and the evidence labels the premium as unjustified, so the valuation does not appear to reflect the full combination of weak results and management volatility.
Near term, results may remain uneven: the company has a record of erratic earnings surprises, and the evidence flags a meaningful chance of a miss. Management has cut operating expenses and says available resources and efficiencies are expected to fund operations into mid-2027, while plans to resubmit the tabelecleucel application with more data remain a key execution task.
The multi-year thesis hinges on whether the updated tabelecleucel submission advances and whether cost reductions preserve the stated operating runway. A guidance cut or further weakening in jobs data would add pressure; continued strength from major Healthcare companies could support the sector backdrop.
Over the next 1 to 3 years, ATRA remains a fragile, execution-dependent long-term thesis, with cost control and regulatory progress still unproven against weak recent performance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Progress resolving FDA Complete Response Letter for EBVALLO | Management is actively working to resolve FDA issues for its key drug EBVALLO. | Improving | No meaningful progress or further FDA setbacks on EBVALLO within next year | Qualitative: BLA accepted by FDA (Oct 2026) vs Target: Regulatory milestones by next 4 quarters FDA accepted the resubmitted tabelecleucel BLA on Oct 14, 2026, following a Type A meeting in May 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sufficient liquidity to fund operations through year-end 2026 | The company plans to fund operations through the end of 2026 with recent cash proceeds and efficiencies. | Broken | liquidity falls short of funding operations through end of 2026 | Cash and cash equivalents: $3.221M FY2026-Q2; GAAP. Published target: Maintain liquidity to fund operations through 2026. Annual target cannot be compared with a quarterly or TTM observation. Date unavailable3,221,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth in line with analyst expectations | A supporting condition in Atara Biotherapeutics Inc's published investment case. The stated target is >=56.7% revenue growth YoY. | Broken | Revenue growth falls below 56.7% YoY next year | Revenue growth: -96.42% FY2026-Q2; GAAP. Published target: >=56.7% revenue growth YoY. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 12, 2026-96.415363 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.90 → $0.94 · observed estimates
$0.04B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.90 | $40,020,000 | 3 / 3 |
| 2026-07-25 | $0.90 | $40,020,000 | 3 / 3 |
| 2026-07-26 | $0.90 | $40,020,000 | 3 / 3 |
| 2026-07-27 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-07-28 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-07-29 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-07-30 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-07-31 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-01 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-02 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-03 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-04 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-05 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-06 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-07 | $0.90 | $40,020,000 | 3 / 3 |
| 2026-08-08 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-09 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-10 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-11 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-12 | $1.27 | $45,075,000 | 3 / 4 |
| 2026-08-13 | $1.40 | $45,075,000 | 2 / 4 |
| 2026-08-14 | $0.90 | $40,020,000 | 3 / 3 |
| 2026-08-15 | $0.90 | $40,020,000 | 2 / 3 |
| 2026-08-16 | $0.90 | $40,020,000 | 2 / 3 |
| 2026-08-17 | $0.90 | $40,020,000 | 2 / 3 |
| 2026-08-18 | $0.90 | $40,020,000 | 3 / 3 |
| 2026-08-19 | $0.90 | $40,020,000 | 3 / 3 |
| 2026-08-20 | $0.90 | $40,020,000 | 3 / 3 |
| 2026-08-21 | $0.50 | $40,786,667 | 3 / 3 |
| 2026-08-22 | $0.50 | $40,786,667 | 3 / 3 |
| 2026-08-23 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-08-24 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-08-25 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-08-26 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-08-27 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-08-28 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-08-29 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-08-30 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-08-31 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-09-01 | $0.40 | $45,590,000 | 2 / 2 |
| 2026-09-02 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-03 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-04 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-05 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-06 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-07 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-08 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-09 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-10 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-11 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-12 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-13 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-14 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-15 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-16 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-17 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-18 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-19 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-20 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-21 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-22 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-23 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-24 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-25 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-26 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-27 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-28 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-29 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-09-30 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-01 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-02 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-03 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-04 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-05 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-06 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-07 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-08 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-09 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-10 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-11 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-12 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-13 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-14 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-15 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-16 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-17 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-18 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-19 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-20 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-21 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-22 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-23 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-24 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-25 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-26 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-27 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-28 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-29 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-30 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-10-31 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-11-01 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-11-02 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-11-03 | $0.94 | $45,650,000 | 2 / 2 |
| 2026-11-04 | $0.94 | $45,650,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.